NASDAQ:IONS - Ionis Pharmaceuticals Stock Price, Price Target & More

Get Started

$44.09 +0.29 (+0.66 %)

(As of 05/24/2018 07:54 AM ET)

Previous Close$43.80

Today's Range$42.74 - $44.55

52-Week Range$39.07 - $65.51

Volume536,543 shs

Average Volume1.41 million shs

Market Capitalization$5.50 billion

P/E Ratio551.13

Dividend YieldN/A

Beta2.45

About Ionis Pharmaceuticals (NASDAQ:IONS)

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein. It is also developing inotersen, an antisense drug Ionis to treat patients with hereditary transthyretin amyloidosis; and volanesorsen, an antisense drug for the treatment of familial chylomicronemia syndrome and familial partial lipodystrophy. In addition, the company is developing drugs for various indications, such as cardiometabolic diseases caused by lipid disorders; cardiovascular disease, clotting disorders, and Alzheimer's and Parkinson's diseases; and acromegaly, amyotrophic lateral sclerosis, beta-thalassemia, and Huntington's disease. Ionis Pharmaceuticals, Inc. has a collaboration agreement with AstraZeneca to discover and develop antisense therapies for treating cardiovascular and metabolic diseases, and cancer; and Biogen Inc. to develop and commercialize therapies for neurological disorders, SMA, and neurodegenerative diseases. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.

Receive IONS News and Ratings via Email

Sign-up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryBiotechnology

SectorMedical

SymbolNASDAQ:IONS

CUSIP46433010

Webwww.ionispharma.com

Phone760-931-9200

Debt

Debt-to-Equity Ratio1.59

Current Ratio5.38

Quick Ratio5.33

Price-To-Earnings

Trailing P/E Ratio551.13

Forward P/E Ratio-1,469.67

P/E GrowthN/A

Sales & Book Value

Annual Sales$507.67 million

Price / Sales10.90

Cash Flow$0.3656 per share

Price / Cash120.61

Book Value$3.08 per share

Price / Book14.31

Profitability

EPS (Most Recent Fiscal Year)$0.08

Net Income$-5,960,000.00

Net Margins-2.00%

Return on Equity-3.06%

Return on Assets-0.88%

Miscellaneous

Employees547

Outstanding Shares125,520,000

Ionis Pharmaceuticals (NASDAQ:IONS) Frequently Asked Questions

What is Ionis Pharmaceuticals' stock symbol?

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

How were Ionis Pharmaceuticals' earnings last quarter?

Ionis Pharmaceuticals Inc (NASDAQ:IONS) released its quarterly earnings results on Friday, May, 4th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.11) by $0.10. The firm had revenue of $144.40 million for the quarter, compared to the consensus estimate of $144.01 million. Ionis Pharmaceuticals had a negative return on equity of 3.06% and a negative net margin of 2.00%. The firm's quarterly revenue was up 24.7% compared to the same quarter last year. During the same quarter last year, the business posted $0.03 EPS. View Ionis Pharmaceuticals' Earnings History.

What price target have analysts set for IONS?

10 brokers have issued 1 year price targets for Ionis Pharmaceuticals' shares. Their forecasts range from $18.00 to $75.00. On average, they anticipate Ionis Pharmaceuticals' stock price to reach $53.30 in the next twelve months. View Analyst Ratings for Ionis Pharmaceuticals.

Who are some of Ionis Pharmaceuticals' key competitors?

Some companies that are related to Ionis Pharmaceuticals include Teva Pharmaceutical Industries (TEVA), Mylan (MYL), BioMarin Pharmaceutical (BMRN), Grifols (GRFS), UCB (UCBJF), Ono Pharmaceutical (OPHLF), Nektar Therapeutics (NKTR), Merck Group (MKGAF), Genmab (GNMSF), Perrigo (PRGO), BeiGene (BGNE), Jazz Pharmaceuticals (JAZZ), Alnylam Pharmaceuticals (ALNY), Valeant Pharmaceuticals Intl (VRX) and SAGE Therapeutics (SAGE).

Who are Ionis Pharmaceuticals' key executives?

Ionis Pharmaceuticals' management team includes the folowing people:

Dr. Stanley T. Crooke, Founder, Exec. Chairman, CEO & Pres (Age 73)
Dr. Brett P. Monia, Founder, COO and Sr. VP of Antisense Drug Discovery & Translational Medicine (Age 57)
Ms. Elizabeth L. Hougen, CFO & Sr. VP of Fin. (Age 56)
Mr. Patrick R. O'Neil, Chief Compliance Officer, Sr. VP of Legal, Gen. Counsel and Corp. Sec. (Age 44)
Ms. B. Lynne Parshall, Sr. Strategic Advisor & Director (Age 64)

Has Ionis Pharmaceuticals been receiving favorable news coverage?

News stories about IONS stock have trended somewhat negative this week, according to Accern Sentiment. Accern identifies positive and negative press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Ionis Pharmaceuticals earned a daily sentiment score of -0.13 on Accern's scale. They also assigned news headlines about the company an impact score of 46.74 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

Who are Ionis Pharmaceuticals' major shareholders?

Ionis Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include BB Biotech AG (6.79%), BlackRock Inc. (5.52%), Baillie Gifford & Co. (4.99%), OppenheimerFunds Inc. (2.29%), Pinnacle Associates Ltd. (0.99%) and American Century Companies Inc. (0.94%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Ionis Pharmaceuticals Inc, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Sarah Boyce and Stanley T Crooke. View Institutional Ownership Trends for Ionis Pharmaceuticals.

Which major investors are selling Ionis Pharmaceuticals stock?

IONS stock was sold by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., JPMorgan Chase & Co., Van ECK Associates Corp, Pinnacle Associates Ltd., BlackRock Inc., Fiera Capital Corp, Altrinsic Global Advisors LLC and A.R.T. Advisors LLC. Company insiders that have sold Ionis Pharmaceuticals company stock in the last year include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Sarah Boyce and Stanley T Crooke. View Insider Buying and Selling for Ionis Pharmaceuticals.

Which major investors are buying Ionis Pharmaceuticals stock?

IONS stock was purchased by a variety of institutional investors in the last quarter, including Summit Trail Advisors LLC, BB Biotech AG, Scout Investments Inc., Sector Gamma AS, Carillon Tower Advisers Inc., OppenheimerFunds Inc., UBS Group AG and Millennium Management LLC. View Insider Buying and Selling for Ionis Pharmaceuticals.

How do I buy shares of Ionis Pharmaceuticals?

Shares of IONS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ionis Pharmaceuticals' stock price today?

One share of IONS stock can currently be purchased for approximately $44.09.

How big of a company is Ionis Pharmaceuticals?

Ionis Pharmaceuticals has a market capitalization of $5.50 billion and generates $507.67 million in revenue each year. The company earns $-5,960,000.00 in net income (profit) each year or $0.08 on an earnings per share basis. Ionis Pharmaceuticals employs 547 workers across the globe.

How can I contact Ionis Pharmaceuticals?

Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The company can be reached via phone at 760-931-9200.

MarketBeat Community Rating for Ionis Pharmaceuticals (IONS)

Community Ranking:		2.5 out of 5 ( )
Outperform Votes:		436 (Vote Outperform)
Underperform Votes:		434 (Vote Underperform)
Total Votes:		870

MarketBeat's community ratings are surveys of what our community members think about Ionis Pharmaceuticals and other stocks. Vote "Outperform" if you believe IONS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IONS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Ionis Pharmaceuticals (NASDAQ:IONS) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

10 Wall Street analysts have issued ratings and price targets for Ionis Pharmaceuticals in the last 12 months. Their average twelve-month price target is $53.30, suggesting that the stock has a possible upside of 20.89%. The high price target for IONS is $75.00 and the low price target for IONS is $18.00. There are currently 2 sell ratings, 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Hold."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Hold	Hold	Hold
Consensus Rating Score:	2.20	2.31	2.31	2.29
Ratings Breakdown:	2 Sell Rating(s) 4 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s)	2 Sell Rating(s) 5 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s)	2 Sell Rating(s) 5 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s)	2 Sell Rating(s) 6 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$53.30	$52.1667	$50.75	$50.3846
Price Target Upside:	20.89% upside	4.21% upside	1.40% upside	7.87% downside

Ionis Pharmaceuticals (NASDAQ:IONS) Consensus Price Target History

Price Target History for Ionis Pharmaceuticals (NASDAQ:IONS)

Ionis Pharmaceuticals (NASDAQ:IONS) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/7/2018	Morgan Stanley	Lower Price Target	Equal Weight ➝ Equal Weight	$52.00	Low
5/7/2018	Stifel Nicolaus	Lower Price Target	Hold ➝ Hold	$57.00	Low
4/23/2018	BMO Capital Markets	Boost Price Target	Outperform ➝ Outperform	$70.00 ➝ $75.00	Medium
2/20/2018	Sanford C. Bernstein	Reiterated Rating	Market Perform	$61.00 ➝ $55.00	Low
10/17/2017	Needham & Company LLC	Reiterated Rating	Buy	$64.00	N/A
10/6/2017	Goldman Sachs Group	Reiterated Rating	Sell ➝ Sell	$30.00	N/A
9/21/2017	Barclays	Lower Price Target	Equal Weight	$55.00 ➝ $52.00	Low
8/16/2017	Evercore ISI	Initiated Coverage	Outperform ➝ Outperform	$65.00	Low
8/14/2017	Laidlaw	Reiterated Rating	Buy	$65.00	Low
8/10/2017	Jefferies Group	Reiterated Rating	Underperform	$17.00 ➝ $18.00	High
5/22/2017	Cowen	Reiterated Rating	Market Perform		Low
5/17/2017	Leerink Swann	Reiterated Rating	Outperform	$47.00 ➝ $45.00	Medium
5/10/2017	Piper Jaffray Companies	Set Price Target	Buy	$66.00 ➝ $51.00	Low
1/5/2017	Janney Montgomery Scott	Set Price Target	Hold	$44.00	N/A
11/10/2016	JPMorgan Chase & Co.	Reiterated Rating	Hold	$35.00	N/A
9/11/2016	Wells Fargo & Co	Reiterated Rating	Buy		N/A

(Data available from 5/24/2016 forward)

Ionis Pharmaceuticals (NASDAQ:IONS) Earnings History and Estimates Chart

Earnings by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Ionis Pharmaceuticals (NASDAQ:IONS) Earnings Estimates

2018 EPS Consensus Estimate: ($0.56)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	2	($0.28)	($0.04)	($0.16)
Q2 2018	2	($0.29)	($0.03)	($0.16)
Q3 2018	2	($0.27)	$0.00	($0.14)
Q4 2018	2	($0.25)	$0.05	($0.10)

Ionis Pharmaceuticals (NASDAQ IONS) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/4/2018	Q1 2018	($0.11)	($0.01)	$144.01 million	$144.40 million	View	N/A
2/27/2018	Q4 2017	($0.08)	$0.02	$126.38 million	$172.00 million	View	N/A
8/8/2017	Q2 2017	($0.06)	($0.09)	$93.29 million	$104.15 million	View	Listen
5/9/2017	Q1 2017	($0.10)	$0.03	$86.03 million	$110.30 million	View	Listen
2/28/2017	Q416	($0.20)	$0.33	$97.47 million	$160.30 million	View	Listen
11/9/2016	Q316	$0.07	$0.06	$114.65 million	$110.90 million	View	Listen
8/9/2016	Q216	($0.52)	($0.47)	$38.52 million	$38.50 million	View	N/A
5/4/2016	Q116	($0.50)	($0.52)	$36.21 million	$36.90 million	View	N/A
2/25/2016	Q415	($0.47)	($0.59)	$49.32 million	$51.60 million	View	Listen
11/9/2015	Q315	($0.31)	($0.30)	$52.93 million	$49.10 million	View	N/A
8/4/2015	Q215	$0.29	$0.29	$114.93 million	$120.40 million	View	N/A
5/5/2015	Q115	($0.19)	($0.14)	$52.74 million	$62.60 million	View	N/A
2/27/2015	Q414	$0.12	$0.25	$74.58 million	$84.90 million	View	N/A
11/7/2014	Q314	($0.20)	($0.23)	$45.79 million	$44.10 million	View	N/A
8/4/2014	Q214	($0.12)	($0.10)	$45.60 million	$57.08 million	View	N/A
5/6/2014	Q114	($0.23)	($0.27)	$35.12 million	$28.20 million	View	N/A
2/28/2014	Q413	($0.17)	($0.21)	$34.20 million	$42.25 million	View	N/A
11/5/2013	Q313	($0.27)	($0.21)	$19.82 million	$23.60 million	View	N/A
8/6/2013	Q2 2013	($0.21)	($0.09)	$26.76 million	$38.10 million	View	Listen
5/7/2013	Q1 2013	($0.02)	($0.02)	$45.24 million	$43.36 million	View	Listen
2/28/2013	Q4 2012	($0.23)	($0.03)	$15.78 million	$19.90 million	View	Listen
11/6/2012	Q312	($0.26)	($0.37)	$23.11 million	$11.60 million	View	N/A
8/6/2012		($0.08)	($0.01)			View	N/A
5/8/2012		($0.28)	($0.24)			View	N/A
2/29/2012		($0.13)	($0.20)			View	N/A
11/7/2011		($0.20)	($0.27)			View	N/A
8/4/2011		($0.22)	($0.18)			View	N/A
5/5/2011		($0.19)	($0.20)			View	N/A
2/28/2011		($0.22)	($0.14)			View	N/A
11/4/2010	Q3 2010	($0.20)	($0.13)			View	N/A
8/9/2010	Q2 2010	($0.15)	($0.25)			View	N/A
5/6/2010	Q1 2010	($0.17)	($0.10)			View	N/A
3/1/2010	Q4 2009	($0.11)	($0.16)			View	N/A
11/5/2009	Q3 2009	($0.05)	($0.07)			View	N/A
8/6/2009	Q2 2009	($0.01)	($0.03)			View	N/A
5/7/2009	Q1 2009	($0.04)	$0.03			View	N/A
2/25/2009	Q4 2008	($0.03)	($0.06)			View	N/A
11/10/2008	Q3 2008	($0.05)	$0.03			View	N/A
8/7/2008	Q2 2008	($0.05)	($0.02)			View	N/A
5/12/2008	Q1 2008	($0.11)	($0.05)			View	N/A
3/13/2008	Q4 2007		($0.08)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Ionis Pharmaceuticals (NASDAQ:IONS) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Ionis Pharmaceuticals (NASDAQ IONS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.13%
Institutional Ownership Percentage: 91.06%

Insider Trading History for Ionis Pharmaceuticals (NASDAQ:IONS)

Ionis Pharmaceuticals (NASDAQ IONS) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/11/2018	C Frank Bennett	SVP	Sell	12,500	$45.00	$562,500.00	31,614
5/11/2018	Joseph H Wender	Director	Sell	15,000	$45.31	$679,650.00	36,649
4/17/2018	Stanley T Crooke	Chairman	Sell	13,962	$44.40	$619,912.80	56,714
3/29/2018	Joseph Klein III	Director	Sell	2,000	$46.15	$92,300.00	11,939
3/15/2018	Joseph Klein III	Director	Sell	2,000	$51.13	$102,260.00
3/12/2018	Patrick R O'neil	SVP	Sell	1,000	$55.00	$55,000.00	15,452
2/28/2018	Joseph Klein III	Director	Sell	3,000	$51.91	$155,730.00	10,839
2/15/2018	Joseph Klein III	Director	Sell	3,000	$48.99	$146,970.00	11,339
2/1/2018	C Frank Bennett	SVP	Sell	12,500	$52.50	$656,250.00
1/30/2018	Joseph Klein III	Director	Sell	3,000	$52.86	$158,580.00
1/29/2018	Patrick R O'neil	SVP	Sell	355	$55.00	$19,525.00	14,507
1/29/2018	Stanley T Crooke	Chairman	Sell	11,000	$54.12	$595,320.00
1/25/2018	Patrick R O'neil	SVP	Sell	645	$55.00	$35,475.00	15,097
1/16/2018	B Lynne Parshall	Director	Sell	5,986	$51.76	$309,835.36	44,166
1/16/2018	Brett P Monia	COO	Sell	2,821	$51.76	$146,014.96	18,604
1/16/2018	C Frank Bennett	SVP	Sell	2,696	$51.76	$139,544.96	21,810
1/16/2018	Elizabeth L Hougen	CFO	Sell	2,724	$51.76	$140,994.24	17,224
1/16/2018	Sarah Boyce	Insider	Sell	2,196	$51.76	$113,664.96	11,127
1/15/2018	Stanley T Crooke	Chairman	Sell	16,549	$51.76	$856,576.24	67,626
1/8/2018	Stanley T Crooke	Chairman	Sell	11,000	$52.01	$572,110.00	48,014
1/3/2018	Stanley T Crooke	Chairman	Sell	22,000	$50.01	$1,100,220.00	58,014
1/2/2018	Brett P Monia	SVP	Sell	163	$50.00	$8,150.00	11,782
12/29/2017	Joseph Klein III	Director	Sell	3,000	$50.56	$151,680.00
12/29/2017	Joseph Klein III	Director	Sell	3,000	$50.56	$151,680.00	12,939
12/15/2017	Elizabeth L Hougen	SVP	Sell	5,000	$52.55	$262,750.00	15,392
12/15/2017	Joseph Klein III	Director	Sell	3,000	$51.69	$155,070.00	12,939
12/4/2017	Elizabeth L Hougen	SVP	Sell	4,000	$57.00	$228,000.00	14,392
12/1/2017	Patrick R O'neil	SVP	Sell	1,000	$55.50	$55,500.00	11,433
11/30/2017	Joseph Klein III	Director	Sell	3,000	$53.55	$160,650.00	12,939
11/29/2017	Elizabeth L Hougen	SVP	Sell	6,000	$53.02	$318,120.00	16,392
11/16/2017	Elizabeth L Hougen	SVP	Sell	7,000	$54.35	$380,450.00	17,392
11/15/2017	Joseph Klein III	Director	Sell	2,250	$53.56	$120,510.00	9,377
11/13/2017	Joseph Klein III	Director	Sell	3,000	$55.39	$166,170.00	7,127
11/1/2017	Patrick R O'neil	SVP	Sell	1,000	$58.35	$58,350.00	11,433
10/18/2017	B Lynne Parshall	COO	Sell	16,118	$65.00	$1,047,670.00	33,526
10/18/2017	C Frank Bennett	SVP	Sell	12,250	$65.00	$796,250.00	27,291
10/13/2017	Richard S Geary	SVP	Sell	8,268	$60.00	$496,080.00
10/13/2017	Stanley T Crooke	Chairman	Sell	16,500	$59.46	$981,090.00
10/5/2017	Patrick R O'neil	SVP	Sell	1,000	$55.00	$55,000.00
10/4/2017	Stanley T Crooke	Chairman	Sell	27,500	$52.89	$1,454,475.00
10/2/2017	Stanley T Crooke	CEO	Sell	15,000	$52.00	$780,000.00	43,014
9/6/2017	Patrick R O'neil	SVP	Sell	1,000	$55.00	$55,000.00	10,633
7/24/2017	C Frank Bennett	SVP	Sell	10,000	$59.29	$592,900.00	25,041
7/20/2017	Stanley T Crooke	Chairman	Sell	11,000	$55.35	$608,850.00	48,014
7/19/2017	Ionis Pharmaceuticals Inc	Major Shareholder	Buy	3,125,000	$8.00	$25,000,000.00	28,884,540
7/17/2017	Stanley T Crooke	Chairman	Sell	16,500	$52.45	$865,425.00	53,014
7/3/2017	Brett P Monia	SVP	Sell	309	$51.35	$15,867.15	11,935
7/3/2017	Stanley T Crooke	Chairman	Sell	16,500	$52.10	$859,650.00	51,476
6/1/2017	Patrick R O'neil	SVP	Sell	70	$48.00	$3,360.00	10,369
5/1/2017	Patrick R O'neil	SVP	Sell	650	$48.75	$31,687.50	10,299
4/25/2017	Stanley T Crooke	Chairman	Sell	16,500	$47.81	$788,865.00	53,014
4/24/2017	Patrick R O'neil	SVP	Sell	500	$45.00	$22,500.00	10,523
4/19/2017	Stanley T Crooke	Chairman	Sell	5,500	$43.25	$237,875.00	43,014
4/13/2017	Stanley T Crooke	Chairman	Sell	22,000	$40.69	$895,180.00	48,014
4/12/2017	Patrick R O'neil	SVP	Sell	1,000	$40.07	$40,070.00	10,449
3/3/2017	C Frank Bennett	SVP	Sell	5,000	$55.00	$275,000.00	19,788
3/1/2017	B Lynne Parshall	COO	Sell	4,625	$49.26	$227,827.50	30,276
3/1/2017	Patrick R O'neil	SVP	Sell	1,500	$49.29	$73,935.00	12,949
2/6/2017	Patrick R O'neil	SVP	Sell	1,500	$46.17	$69,255.00	12,449
1/17/2017	B Lynne Parshall	COO	Sell	7,246	$46.29	$335,417.34	19,459
1/17/2017	Brett P Monia	SVP	Sell	2,502	$46.29	$115,817.58	9,287
1/17/2017	Elizabeth L Hougen	CFO	Sell	2,273	$46.29	$105,217.17	7,059
1/17/2017	Sarah Boyce	Insider	Sell	1,361	$46.29	$63,000.69	5,318
1/17/2017	Stanley T Crooke	CEO	Sell	15,382	$46.29	$712,032.78	30,576
1/10/2017	Stanley T Crooke	Chairman	Sell	13,200	$49.25	$650,100.00	37,029
1/4/2017	Stanley T Crooke	Chairman	Sell	18,700	$48.89	$914,243.00	30,029
1/3/2017	Brett P Monia	SVP	Sell	309	$48.60	$15,017.40	8,181
12/20/2016	Brett P Monia	SVP	Sell	130	$52.48	$6,822.40	7,872
12/15/2016	B Lynne Parshall	COO	Sell	4,000	$50.00	$200,000.00	16,693
12/5/2016	Elizabeth L Hougen	CFO	Sell	2,500	$46.05	$115,125.00	9,048
12/5/2016	Patrick R O'neil	SVP	Sell	350	$45.00	$15,750.00	9,876
12/1/2016	B Lynne Parshall	COO	Sell	12,500	$42.23	$527,875.00	23,693
11/14/2016	Patrick R O'neil	SVP	Sell	1,000	$45.00	$45,000.00	9,720
11/11/2016	Elizabeth L Hougen	SVP	Sell	5,000	$39.75	$198,750.00	9,048
11/7/2016	C Frank Bennett	SVP	Sell	5,000	$34.00	$170,000.00	15,803
10/5/2016	Stanley T Crooke	Chairman	Sell	11,000	$36.61	$402,710.00	35,029
9/27/2016	Stanley T Crooke	Chairman	Sell	22,000	$36.02	$792,440.00	45,029
9/21/2016	Stanley T Crooke	Chairman	Sell	22,000	$35.50	$781,000.00	45,029
9/1/2016	B Lynne Parshall	COO	Sell	12,500	$29.88	$373,500.00	25,558
5/31/2016	Frederick T Muto	Director	Sell	12,500	$22.31	$278,875.00	15,043
4/6/2016	Patrick R O'neil	SVP	Sell	1,000	$45.00	$45,000.00	10,124
4/6/2016	Stanley T Crooke	CEO	Sell	11,000	$46.13	$507,430.00	30,029
3/31/2016	Stanley T Crooke	CEO	Sell	11,000	$40.74	$448,140.00	30,029
3/23/2016	Patrick R O'neil	SVP	Sell	1,000	$45.40	$45,400.00	10,124
1/19/2016	B Lynne Parshall	COO	Sell	5,192	$41.46	$215,260.32	16,290
1/19/2016	C Frank Bennett	SVP	Sell	2,110	$41.46	$87,480.60	10,590
1/19/2016	Elizabeth L. Hougen	CFO	Sell	1,899	$41.46	$78,732.54	6,331
1/19/2016	Sarah Boyce	insider	Sell	872	$41.46	$36,153.12	1,735
1/19/2016	Stanley T. Crooke	CEO	Sell	13,401	$41.46	$555,605.46	25,029
1/5/2016	Stanley T. Crooke	CEO	Sell	5,500	$62.10	$341,550.00	14,642
1/4/2016	B Lynne Parshall	COO	Sell	809	$61.05	$49,389.45	8,215
1/4/2016	Brett P. Monia	SVP	Sell	127	$61.00	$7,747.00	4,358
1/4/2016	Stanley T. Crooke	CEO	Sell	11,000	$61.05	$671,550.00	14,642
12/16/2015	C Frank Bennett	SVP	Sell	7,909	$57.41	$454,055.69	7,316
12/1/2015	Patrick R. O'neil	SVP	Sell	1,000	$61.50	$61,500.00	6,259
11/11/2015	Joseph Klein III	Director	Sell	6,875	$64.18	$441,237.50	5,543
11/10/2015	C Frank Bennett	SVP	Sell	5,000	$64.00	$320,000.00	7,316
11/6/2015	C Frank Bennett	SVP	Sell	5,000	$56.00	$280,000.00	7,316
11/3/2015	Patrick R. O'neil	SVP	Sell	1,000	$51.95	$51,950.00	6,259
10/23/2015	Stanley T. Crooke	CEO	Sell	44,000	$43.85	$1,929,400.00	14,642
10/2/2015	B Lynne Parshall	COO	Sell	12,436	$40.75	$506,767.00	8,143
7/6/2015	B Lynne Parshall	COO	Sell	6,218	$57.01	$354,488.18
7/6/2015	Stanley T Crooke	CEO	Sell	5,000	$57.01	$285,050.00
7/1/2015	B Lynne Parshall	COO	Sell	6,218	$57.56	$357,908.08
7/1/2015	Stanley T Crooke	CEO	Sell	6,175	$57.56	$355,433.00
6/8/2015	Brett P Monia	SVP	Sell	7,600	$66.22	$503,272.00
4/7/2015	B Lynne Parshall	COO	Sell	5,565	$63.07	$350,984.55
4/7/2015	Stanley T Crooke	CEO	Sell	22,377	$63.07	$1,411,317.39
3/24/2015	C Frank Bennett	SVP	Sell	15,000	$70.61	$1,059,150.00
3/19/2015	Elizabeth L Hougen	CFO	Sell	10,000	$73.33	$733,300.00
3/19/2015	Patrick R O'neil	SVP	Sell	30,525	$74.85	$2,284,796.25
3/2/2015	Joseph H Wender	Director	Sell	7,000	$65.97	$461,790.00
1/27/2015	Stanley T Crooke	CEO	Sell	11,000	$72.93	$802,230.00
1/16/2015	B Lynne Parshall	COO	Sell	4,093	$67.96	$278,160.28
1/16/2015	Elizabeth L Hougen	CFO	Sell	1,291	$67.96	$87,736.36
1/16/2015	Richard S Geary	SVP	Sell	1,543	$67.96	$104,862.28
1/16/2015	Stanley T Crooke	CEO	Sell	9,054	$67.96	$615,309.84
1/9/2015	Stanley T Crooke	CEO	Sell	11,000	$73.57	$809,270.00
1/7/2015	Stanley T Crooke	CEO	Sell	22,000	$67.04	$1,474,880.00
1/2/2015	B Lynne Parshall	COO	Sell	11,200	$62.12	$695,744.00
1/2/2015	Patrick R O'neil	SVP	Sell	1,500	$62.12	$93,180.00
12/1/2014	Patrick R O'neil	SVP	Sell	1,500	$51.21	$76,815.00
11/3/2014	Patrick R O'neil	SVP	Sell	1,500	$46.17	$69,255.00
10/30/2014	B Lynne Parshall	COO	Sell	11,071	$45.12	$499,523.52
10/23/2014	Stanley T Crooke	CEO	Sell	14,600	$42.22	$616,412.00
10/3/2014	Stanley T Crooke	CEO	Sell	36,000	$38.52	$1,386,720.00
10/1/2014	Patrick R O'neil	SVP	Sell	1,500	$38.04	$57,060.00
10/1/2014	Stanley T Crooke	CEO	Sell	20,000	$37.91	$758,200.00
8/27/2014	C Frank Bennett	SVP	Sell	5,000	$40.53	$202,650.00
8/13/2014	Stanley T Crooke	CEO	Sell	15,500	$35.45	$549,475.00
8/12/2014	Patrick R O'neil	SVP	Sell	1,500	$35.00	$52,500.00
8/1/2014	Stanley T Crooke	CEO	Sell	16,000	$30.53	$488,480.00
7/31/2014	Brett P Monia	SVP	Sell	79	$31.50	$2,488.50
7/1/2014	Patrick R O'neil	SVP	Sell	1,500	$35.33	$52,995.00
7/1/2014	Stanley T Crooke	CEO	Sell	17,500	$35.57	$622,475.00
6/23/2014	C Frank Bennett	SVP	Sell	11,200	$36.78	$411,936.00
6/19/2014	Stanley T Crooke	CEO	Sell	11,000	$35.10	$386,100.00
6/10/2014	Stanley T Crooke	CEO	Sell	11,000	$33.46	$368,060.00
6/2/2014	Frederick T Muto	Director	Sell	10,000	$28.59	$285,900.00
4/2/2014	Stanley Crooke	CEO	Sell	8,800	$43.65	$384,120.00	6,941
1/30/2014	B Lynne Parshall	COO	Sell	89,510	$49.49	$4,429,849.90	4,022
1/24/2014	Joseph Klein III	Director	Sell	10,313	$48.66	$501,830.58	2,313
1/22/2014	Joseph Wender	Director	Sell	10,000	$50.98	$509,800.00	31,135
1/22/2014	Richard Geary	SVP	Sell	22,200	$50.05	$1,111,110.00	4,955
1/16/2014	B Lynne Parshall	COO	Sell	1,641	$47.08	$77,258.28	4,022
1/16/2014	Stanley Crooke	CEO	Sell	3,527	$47.08	$166,051.16	6,941
1/8/2014	Richard Geary	SVP	Sell	15,000	$40.45	$606,750.00	3,610
1/8/2014	Stanley Crooke	CEO	Sell	12,500	$40.05	$500,625.00	1,661
1/2/2014	Stanley Crooke	CEO	Sell	31,500	$39.35	$1,239,525.00	1,661
12/26/2013	B Lynne Parshall	COO	Sell	37,811	$40.91	$1,546,848.01	956
12/24/2013	B Lynne Parshall	COO	Sell	70,000	$41.49	$2,904,300.00	956
12/20/2013	Joseph Wender	Director	Sell	19,731	$39.58	$780,952.98	41,135
12/5/2013	C Frank Bennett	SVP	Sell	10,000	$39.92	$399,200.00	2,866
11/26/2013	Joseph Wender	Director	Sell	10,000	$36.63	$366,300.00	45,866
9/20/2013	B Lynne Parshall	COO	Sell	90,000	$35.43	$3,188,700.00	956
9/20/2013	Brett Monia	SVP	Sell	68,281	$34.21	$2,335,893.01	769
9/20/2013	Stanley Crooke	CEO	Sell	58,740	$35.19	$2,067,060.60	1,661
9/19/2013	C Frank Bennett	SVP	Sell	10,000	$35.02	$350,200.00	2,866
9/11/2013	B Lynne Parshall	COO	Sell	63,505	$31.04	$1,971,195.20
9/9/2013	C Frank Bennett	SVP	Sell	10,000	$30.23	$302,300.00
9/4/2013	Patrick R O'neil	SVP	Sell	2,500	$27.09	$67,725.00
8/26/2013	Brett Monia	SVP	Sell	2,909	$25.58	$74,412.22	769
8/9/2013	Joseph Klein III	Director	Sell	18,750	$28.22	$529,125.00	8,313
7/23/2013	Stanley T Crooke	COO	Sell	11,500	$30.00	$345,000.00
7/22/2013	Stanley T Crooke	CEO	Sell	62,200	$30.50	$1,897,100.00
7/17/2013	Stanley T Crooke	CEO	Sell	49,300	$33.12	$1,632,816.00
7/12/2013	Stanley T Crooke	CEO	Sell	90,000	$31.75	$2,857,500.00
7/11/2013	Richard S Geary	SVP	Sell	9,000	$31.90	$287,100.00
7/9/2013	Richard S Geary	SVP	Sell	66,163	$30.03	$1,986,874.89
7/9/2013	Stanley T Crooke	CEO	Sell	109,172	$26.69	$2,913,800.68
7/3/2013	Richard S Geary	SVP	Sell	5,000	$29.02	$145,100.00
7/1/2013	Stanley T Crooke	CEO	Sell	50,683	$27.65	$1,401,384.95
6/26/2013	Stanley T Crooke	CEO	Sell	90,000	$26.73	$2,405,700.00
6/25/2013	Richard S Geary	SVP	Sell	47,049	$26.20	$1,232,683.80
6/20/2013	Joseph H Wender	Director	Sell	5,447	$20.93	$114,005.71
6/11/2013	Brett P Monia	SVP	Sell	9,375	$23.76	$222,750.00
5/30/2013	Frederick T Muto	Director	Sell	10,000	$21.96	$219,600.00
1/16/2013	Stanley T Crooke	CEO	Sell	1,460	$14.00	$20,440.00

(Data available from 1/1/2013 forward)

Ionis Pharmaceuticals (NASDAQ IONS) News Headlines

Source:

Date	Headline
	Webcast Alert: Ionis Pharmaceuticals Provides Corporate Update at 2018 Annual Meeting of Stockholders finance.yahoo.com - May 23 at 8:32 AM
	Ionis Pharmaceuticals Inc (IONS) Expected to Announce Quarterly Sales of $116.58 Million www.americanbankingnews.com - May 21 at 3:58 AM
	Ionis Pharmaceuticals Inc (IONS) Given Consensus Rating of "Hold" by Analysts www.americanbankingnews.com - May 20 at 11:31 AM
	Brokerages Expect Ionis Pharmaceuticals (IONS) to Announce -$0.02 Earnings Per Share www.americanbankingnews.com - May 19 at 12:11 PM
	Ionis And Akcea Obtain Positive Recommendation From Panel, Can They Go All The Way? seekingalpha.com - May 14 at 8:51 AM
	Ionis Pharmaceuticals (IONS) SVP Sells $562,500.00 in Stock www.americanbankingnews.com - May 11 at 10:27 PM
	Insider Selling: Ionis Pharmaceuticals (IONS) Director Sells 15,000 Shares of Stock www.americanbankingnews.com - May 11 at 10:21 PM
	Ionis and Akcea up premarket after Ad Com vote seekingalpha.com - May 11 at 8:57 AM
	FDA Advisory Committee Votes in Favor of WAYLIVRA for Treatment of Familial Chylomicronemia Syndrome finance.yahoo.com - May 11 at 8:57 AM
	Ionis Pharmaceuticals (IONS) Cut to Hold at Zacks Investment Research www.americanbankingnews.com - May 10 at 4:40 PM
	Ionis Pharmaceuticals (IONS) Raised to Strong-Buy at Zacks Investment Research www.americanbankingnews.com - May 9 at 6:57 PM
	Biotech Analysis Central Pharma News: Takeda's Acquisition Win, Ionis And Akcea Tumble, Alnylam's Advance In CNS seekingalpha.com - May 9 at 8:37 AM
	Ionis Pharmaceuticals (IONS) Downgraded by ValuEngine www.americanbankingnews.com - May 8 at 11:26 PM
	Evercore ISI Lowers Ionis Pharmaceuticals (IONS) to Outperform www.americanbankingnews.com - May 8 at 3:45 PM
	Ionis Pharmaceuticals (IONS) Q1 2018 Earnings Conference Call Transcript finance.yahoo.com - May 7 at 5:24 PM
	Ionis Pharmaceuticals (IONS) Price Target Cut to $51.00 by Analysts at Morgan Stanley www.americanbankingnews.com - May 7 at 3:16 PM
	Ionis Pharmaceuticals (IONS) Stock Rating Reaffirmed by Stifel Nicolaus www.americanbankingnews.com - May 7 at 2:58 PM
	There Are Better Ideas Than Ionis Pharma (IONS) - Goldman Sachs www.streetinsider.com - May 7 at 8:34 AM
	Edited Transcript of IONS earnings conference call or presentation 4-May-18 3:30pm GMT finance.yahoo.com - May 5 at 5:23 PM
	Ionis Pharmaceuticals' (IONS) CEO Stan Crooke on Q1 2018 Results - Earnings Call Transcript seekingalpha.com - May 5 at 8:44 AM
	Ionis Pharmaceuticals (IONS) Posts Quarterly Earnings Results, Misses Expectations By $0.05 EPS www.americanbankingnews.com - May 4 at 8:33 PM
	Ionis Pharma Q1 revenues up 25% seekingalpha.com - May 4 at 5:14 PM
	Ionis (IONS) Beats Earnings & Misses Revenues in Q1 finance.yahoo.com - May 4 at 5:14 PM
	10 Ionis Pharmaceuticals Inc Earnings Highlights investorplace.com - May 4 at 1:50 PM
	Ionis Pharmaceuticals beats by $0.03, beats on revenue seekingalpha.com - May 4 at 8:33 AM
	Ionis Reports First Quarter 2018 Financial Results finance.yahoo.com - May 4 at 8:33 AM
	Ionis Pharma shares lift 4% after Q1 profit, revenue beats finance.yahoo.com - May 4 at 8:33 AM
	Ionis Pharmaceuticals: 1Q Earnings Snapshot finance.yahoo.com - May 4 at 8:33 AM
	Brokerages Anticipate Ionis Pharmaceuticals (IONS) Will Announce Quarterly Sales of $159.81 Million www.americanbankingnews.com - May 3 at 1:55 AM
	-$0.11 EPS Expected for Ionis Pharmaceuticals (IONS) This Quarter www.americanbankingnews.com - May 1 at 11:14 PM
	Biogen's $1 Billion Bet on Ionis www.fool.com - April 30 at 5:03 PM
	Biogen's $1 Billion Bet on Ionis finance.yahoo.com - April 30 at 5:03 PM
	Ionis Pharmaceuticals: The Pinnacle Of RNA Therapeutic Innovation seekingalpha.com - April 30 at 8:40 AM
	Ionis Pharmaceuticals (IONS) Scheduled to Post Quarterly Earnings on Monday www.americanbankingnews.com - April 30 at 7:23 AM
	Biogen's Ionis Deal Is Brilliant seekingalpha.com - April 25 at 5:17 PM
	Biogen-Ionis Expansion Builds on Spinraza Success finance.yahoo.com - April 25 at 5:17 PM
	How Did Biogen’s Spinraza Perform in 1Q18? finance.yahoo.com - April 25 at 5:17 PM
	Ionis Pharmaceuticals (IONS) Given Consensus Recommendation of "Hold" by Brokerages www.americanbankingnews.com - April 25 at 11:20 AM
	New Data from IONIS-HTT Rx Phase 1/2 Study Demonstrates Correlation Between Reduction of Disease-causing Protein and Improvement in Clinical Measures of Huntington's Disease finance.yahoo.com - April 24 at 5:24 PM
	Why Ionis Pharmaceuticals Crashed Today finance.yahoo.com - April 24 at 5:24 PM
	Ionis Pharmaceuticals to Hold First Quarter 2018 Financial Results Webcast finance.yahoo.com - April 24 at 8:35 AM
	Ionis Pharmaceuticals (IONS) Upgraded to "Hold" at ValuEngine www.americanbankingnews.com - April 23 at 11:18 PM
	Ionis Pharmaceuticals (IONS) Updates on New Expanded and Extended Strategic Collaboration with Biogen - Slideshow seekingalpha.com - April 23 at 5:02 PM
	Ionis: Superb Neurological Pipeline With 5 Additional Pipelines Of Note seekingalpha.com - April 23 at 5:02 PM
	Ionis Pharmaceuticals (IONS) PT Raised to $75.00 at BMO Capital Markets www.americanbankingnews.com - April 23 at 10:54 AM
	Ahead of earnings, Biogen’s Ionis deal perplexes www.marketwatch.com - April 23 at 8:27 AM
	Ionis Pharmaceuticals (IONS) in Focus: Stock Moves 5.8% Higher www.zacks.com - April 23 at 8:27 AM
	US STOCKS ON THE MOVE-Twitter, GE, Pinnacle Foods, TransUnion, Ionis Pharma www.nasdaq.com - April 22 at 6:19 PM
	Biogen plunks down $1B in cash to expand neuro drug pact with Ionis www.bizjournals.com - April 20 at 5:09 PM
	Ionis Pharmaceuticals (IONS) Chairman Sells $619,912.80 in Stock www.americanbankingnews.com - April 19 at 7:34 PM

Ionis Pharmaceuticals (NASDAQ:IONS) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Ionis Pharmaceuticals (NASDAQ:IONS) Income Statement, Balance Sheet and Cash Flow Statement

Ionis Pharmaceuticals (NASDAQ IONS) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff